Lucid Diagnostics Inc. (NASDAQ: LUCD) closed an underwritten public offering of 18 million common shares at $1.00 per share, raising approximately $18 million in gross proceeds before fees and expenses.

The cancer diagnostics company said the offering was anchored by a $15 million investment from an institutional investor with additional support from an existing shareholder. Lucid plans to use the net proceeds for working capital and general corporate purposes.

Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners for the offering. The securities were sold under a shelf registration statement that became effective March 26, 2026.

Lucid Diagnostics, a subsidiary of PAVmed Inc. (NASDAQ: PAVM), develops medical diagnostic tools for esophageal cancer prevention. The company markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for detecting esophageal precancer in patients with gastroesophageal reflux disease.